Vice President Clinical Development
Lycia Therapeutics
Vice President Clinical Development
Lycia Therapeutics
Degrades extracellular proteins with LYTAC platform
Salary Range: 360000 to 420000 (Currency: USD) (Pay period: per-year-salary)
Lycia Therapeutics (Nasdaq: LYCA) is a clinical-stage biotechnology company using its proprietary lysosomal targeting chimera (LYTAC) platform to discover and develop therapeutics that degrade extracellular and membrane-bound proteins. These proteins drive a wide range of difficult-to-treat diseases, including autoimmune, inflammatory, and allergic conditions. Lycia was established in 2019 in collaboration with academic founder and Nobel Laureate Carolyn Bertozzi, Ph.D., professor of chemistry and HHMI investigator at Stanford University. In October 2026, Lycia completed an initial public offering, and its common stock now trades on the Nasdaq Global Select Market under the ticker symbol “LYCA.” Lycia is headquartered in South San Francisco.
Visit https://lyciatx.com/ for more information.
Position Summary
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Lycia and other biotech companies have recently noticed an increase in email and social media scams targeting job candidates in our industry. Please note Lycia will post any legitimate job openings directly on our website or through our recruitment partner, Lever. If you wish to verify the legitimacy of a job opening, you may contact us.
We may use artificial intelligence (AI) tools to support parts of the hiring process, such as reviewing applications, analyzing resumes, or assessing responses. These tools assist our recruitment team but do not replace human judgment. Final hiring decisions are ultimately made by humans.
Degrades extracellular proteins with LYTAC platform
Lycia Therapeutics develops therapeutics using its LYTAC platform to degrade extracellular and membrane proteins involved in autoimmune and inflammatory diseases, and potentially cancer. LYTACs are bifunctional molecules where one end binds the disease protein and the other end binds a cell-surface receptor that routes the complex to the lysosome for destruction. This targets proteins outside the cell that are inaccessible to intracellular degraders like PROTACs, enabling collaborations with pharma partners to share development risk. The goal is to bring first-in-class LYTAC degraders into clinical trials, advance an autoimmune/inflammatory disease pipeline, and pursue partnerships that drive milestones and royalties.
Explore more opportunities at Lycia Therapeutics